Protocol Ledger

NCT05027867 · Phase II · TERMINATED

KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer

Interventional Phase II clinical trial protocol NCT05027867 sponsored by Kartos Therapeutics in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-12-06 Enrollment: 3 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05027867
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)3 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05027867
Protocol FieldVerified Registry Value
NCT IdentifierNCT05027867
Consolidated Lead SponsorKartos Therapeutics
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment3 participants (ACTUAL)
Registered Start Date2021-12-06
WhyStopped ClassificationSafety / Toxicity / Adverse Events

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI